Related Experiment Videos
Development of a defined medium fermentation process for physostigmine production by Streptomyces griseofuscus
J Zhang1, C Marcin, M A Shifflet
1Department of Bioprocess R&D, Merck Research Laboratories, New Jersey 07065, USA.
Applied Microbiology and Biotechnology
|January 1, 1996
Summary
Researchers optimized physostigmine production using Streptomyces griseofuscus fermentation. This enhanced Alzheimer
Area of Science:
- Biotechnology
- Microbial Production
- Pharmacology
Background:
- Physostigmine, a plant alkaloid, shows therapeutic potential for Alzheimer's disease.
- Streptomyces griseofuscus NRRL 5324 naturally produces physostigmine.
- Submerged cultivation is a viable method for microbial production.
Purpose of the Study:
- To develop an optimized fermentation process for physostigmine production.
- To increase physostigmine yield from Streptomyces griseofuscus.
- To establish a scalable and efficient production method.
Main Methods:
- Development of a chemically defined medium for fermentation.
- Statistical experimentation for medium optimization.
- Scale-up studies in shake-flasks and bioreactors (23-L and 800-L).
- Implementation of a nutrient-feeding strategy in large-scale fermentation.
Main Results:
- Physostigmine titer increased from 20 mg/l to 520 mg/l in shake-flasks.
- Yield reached 790 mg/l in a 23-L bioreactor.
- A final titer of 880 mg/l was achieved in an 800-L fermentor.
- Overall production showed a 44-fold increase compared to the initial process.
- The fermentation broth facilitated downstream processing.
Conclusions:
- Optimized fermentation significantly enhances physostigmine production by Streptomyces griseofuscus.
- The developed process is scalable and efficient for industrial application.
- This method provides a sustainable source of physostigmine for Alzheimer's disease treatment research.